Friday 6 November 2026
Export TVTX’s income statement to Excel — free account
Travere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
49.45
0.58
+1.19%
Follow TVTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 6 | 6 | 6 |
+8 more TTM periods Free account |
| (252.75%) | (151.79%) | (32.57%) | (29.38%) | ||
| (17.52%) | (6.42%) | (3.88%) | (4.26%) | ||
ROIC |
(54.08%) | (18.31%) | (24.41%) | (37.84%) | |
Return on Tangible Assets |
(28.57%) | (9.32%) | (7.91%) | (9.07%) | |
Average Days of Receivables |
60.29 | 49.77 | 59.43 | 59.60 | |
Free Cash Flow per Share |
0.90 | 0.16 | (0.31) | (0.23) | |
Free Cash Flow |
85.35 | 15.16 | (28.94) | (20.37) | |
Capital Expenditures |
(91.24) | (77.54) | (68.55) | (58.16) | |
| Other line items | |||||
Cash ROIC |
7.77% | 1.36% | (4.28%) | (2.72%) | |
Accounts Receivable Turnover |
6.83 | 9.91 | 8.81 | 9.15 | |
Accounts Payable Turnover |
0.57 | 0.62 | 0.54 | 0.43 | |
Inventory Turnover |
1.19 | 1.39 | 1.48 | 1.71 | |
Average Days of Payables |
584.46 | 331.08 | 619.30 | 875.52 | |
Days of Inventory on Hand |
402.13 | 346.09 | 304.85 | 207.41 | |
Tax Rate |
(0.03) | 0.01 | 0.02 | 0.02 | |
Research and Development Expense of Revenue |
55.09% | 38.41% | 40.32% | 41.98% | |
Selling, General and Administrative Expense of Revenue |
61.83% | 66.05% | 66.59% | 68.71% | |
Share Based Compensation of Revenue |
11.19% | 10.26% | 9.24% | 9.14% | |
Interest Coverage |
(15.05) | (4.27) | (5.60) | (5.85) | |
Operating CF/Net income |
(1.45) | (2.13) | (1.85) | (1.48) | |
Depreciation/Fixed assets |
18.35 | 18.75 | 19.40 | 14.41 | |
Capex/Depreciation |
(1.83) | (1.28) | (0.97) | (1.00) | |
Revenue per Share |
6.88 | 6.33 | 5.84 | 5.50 | |
Operating CF per Share |
1.87 | 0.99 | 0.43 | 0.42 | |
Capex per Share |
(0.96) | (0.83) | (0.75) | (0.65) | |
Capex to Sales |
0.14 | 0.13 | 0.13 | 0.12 |
Columns are period end dates · fundamentals updated 6 Nov 2026